Company intelligence / Profile preview
Sumitovant Biopharma
New York City, New York, United Statessumitovant.com ↗
- Ownership
- Private
- Employees
- ~246
- Development stage
- Other
01
Overview
Sumitovant supported the development of multiple FDA-approved products including ORGOVYX® for prostate cancer and GEMTESA® for overactive bladder. Its portfolio included both commercialized drugs and a robust pipeline addressing unmet needs in pediatrics, urology, oncology, women’s health, specialty respiratory diseases, and infectious diseases.
- Therapeutic areas
- PulmonologyUrologyWomen's HealthOncologyRare Diseases
- Modalities
- Small moleculeMonoclonal antibodyGene therapyCell therapyRNA therapy
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
Pfizer partnership with Myovant on relugolix/ORGOVYX® commercialization in oncology/women's health in US/Canada; Pfizer option ex-US/excluded Asia.
Beyond the preview
Go deeper on Sumitovant Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sumitovant Biopharma.